Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects

Reuters

2025/08/28

Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's <a href="https://laohu8.com/S/CCOOF">Core Assets</a> to Boost U.S. Listing Prospects

Argent BioPharma Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis® patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil® and CimetrA®, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60454) on August 27, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562544773"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562544773\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562544773?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562544773","market":"us","top_or_hot":-1,"title":"Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's <a href=\"https://laohu8.com/S/CCOOF\">Core Assets</a> to Boost U.S. Listing Prospects\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MGCLF\">Argent BioPharma</a> Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis® patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil® and CimetrA®, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60454) on August 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-28 05:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's <a href=\"https://laohu8.com/S/CCOOF\">Core Assets</a> to Boost U.S. Listing Prospects\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MGCLF\">Argent BioPharma</a> Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis® patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil® and CimetrA®, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60454) on August 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL7qR0GW:1","article_id":"2562544773","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562544773","pubTimestamp":1756330244,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Argent BioPharma Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil and CimetrA, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","RGT.AU":"Argent BioPharma Limited"},"translate_title":"Argent Biopharma Ltd.宣布战略收购AusCann核心资产提振美国上市前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGT.AU":0.9},"content_text":"Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects\n    \n\nArgent BioPharma Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis® patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil® and CimetrA®, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60454) on August 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}